News

CHS Resources will develop and ultimately commercialize patent pending technology for the treatment of skin cancer. The technology was discovered by Dr Herbert Weissbach, director of the Center

The trial is expected to enroll approximately 100 patients at multiple sites in the US. Patients will be evaluated for a total of nine weeks including a four-week

The newly approved products are the extended-release (ER) and immediate-release formulations of oxymorphone hydrochloride. Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous,

The first analysis demonstrated the ability of Humira to maintain the reduction of signs and symptoms in ankylosing spondylitis (AS) patients at 12 weeks through 52 weeks of

The collaboration will encompass the development of therapeutic antibodies against proteins identified by Celera’s proteomic research discovery efforts as being over-expressed on the surface of tumor cells and

The company has begun patient enrollment in a phase IIa trial that will examine safety and tolerability, dosing, and the effect of different dose levels on platelet function

During the trial, hypogonadal men, receive Nebido via intramuscular injection every 12 weeks. The primary endpoint in the pharmacokinetic trial is the assessment of average serum testosterone levels

Avigen is developing AV650 in the North American market under a license and supply agreement with Sanochemia Pharmazeutika AG. The compound is already marketed in Europe and Asia

According to results, presented by the company at the Annual European Congress of Rheumatology in Amsterdam, the compound significantly reduced disease activity, exhibited clinically relevant bioactivity, and was